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Abstract:   
Diammonium glycyrrhizinate (DG), a constitutent of Glycyrrhiza uralensis, has a protective 
effect on hepatic injury, hepatisis and cirrhosis. To date, the mechanism has been poorly 
understood, especially at the metabolic level. A metabolomic profiling study was performed to 
characterize the carbon tetrachloride (CCl4) induced global metabolic alteration and the 
protective effects of DG in Sprague-Dawley rats. Urinary and hepatic tissue metabolic profiling 
revealed that CCl4 perturbed the amino acid metabolism (alanine, glycine, leucine), tricarboxylic 
acid cycle (citrate), lipid metabolism (unsaturated fatty acids) and gut microbiota related 
metabolites. Our results also indicated that DG was able to attenuate CCl4 perturbed metabolic 
pathways and ameliorated biochemical markers of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and Total cholesterol (TCHO). This global metabolomic approach also 
revealed full metabolic recovery takes longer than apparent and conventional histological and 
biochemical markers.  
 
Article: 
INTRODUCTION 
Diammonium glycyrrhizinate (DG), a purified effective constituent of the traditional Chinese 
medicinal herb Glycyrrhiza uralensis (liquorices or Gan-Cao) is clinically used in the treatment 
of hepatic injury, hepatisis and cirrhosis (Feng et al. 2007). DG possesses a high anti-
inflammatory effect, which protects the hepatic cell membrane, and ameliorates liver function 
(Xu et al. 2009; Yuan et al. 2006). It would undoubtedly be beneficial to understand the 
mechanisms of the hepatoprotective effect of this herbal ingredient in metabolic regulation. 
Carbon tetrachloride (CCl4) is a widely used hepatotropic poison which induces experimental 
liver damage histologically as hepatic steatosis, cellular necrosis, fibrosis, hepatocellular death 
and carcinogenicity (Weber et al. 2003). Because the CCl4 induced hepatic injury model can 
clearly reflect the function, metabolism and morphological variations of hepatic cells with high 
reproducibility, the model is commonly used to simulate acute/chronic hepatitis (Okamoto and 
Okabe 2000; Cherkashina and Petrenko 2006) and hepatic fibrosis (Abdel-Salam et al. 2007). 
The metabolic impact of CCl4 has been evaluated by profiling differential expressed metabolites 
of plasma, tissue and urine during poisoning process (Robertson et al. 2000; Pan et al. 2010; Lin 
et al. 2009). In this study, we set up an acute hepatic injury animal model with CCl4 to test the 
biochemical and metabolic mechanism of the anti-hepatotoxicity of DG.  
 
Metabolic profiling of biological samples using GC/MS has been extensively used to evaluate 
the toxic/disease status and test the efficacy of drug treatment (Pan et al. 2010; Qiu et al. 2007; 
Wang et al. 2007). This technology provides quantitative information on metabolite levels 
increase or decrease in response to xenobiotic interventions, especially in hepatotoxicity research 
(Chen et al. 2009; Beger et al. 2010; Sun et al. 2009). This information complements organ-
specific biochemical and histological variations and can reveal a complex interplay among 
biochemical regulatory pathways and xenobiotics agents in a given biological system. This study 
aimed to characterize metabolic variations and thus, understand the dynamic pathophysiological 
process associated with the CCl4 induced acute hepatic toxicity and the protective effect of DG 
pre-ingestion in Sprague-Dawley (SD) rats upon treatment of a diammonium glycyrrhizinate 
intervention.  
 
MATERIALS AND METHODS 
Animals and treatments  
A total of 72 Male Sprague-Dawley (SD) rats weighing 200–250 g were commercially obtained 
from Shanghai Laboratory Animal Co., Ltd. (SLAC, Shanghai, China). All animals were kept in 
a barrier system with regulated temperature (23–24°C) and humidity (60 ± 10%) and on a 12/12-
h light–dark cycle with lights on at 08:00 a.m. The rats were fed certified standard rat chow and 
tap water ad libitum for 2 week acclimation. Rats were randomly divided into three groups of 24: 
(A) normal control (NC), (B) CCl4 model (CCl4), (C) DG + CCl4 (DG/CCl4). Each animal in the 
DG/CCl4 group was intragastrically administered 46.88 mg kg−1 of DG (dissolved in saline), 
while rats in the NC and CCl4 groups received the same volume of saline, once a day for 
14 days. On the 14th day, each animal in the CCl4 and DG/CCl4 group received an 
intraperitoneal injection of CCl4 in olive oil (25% v/v) at 1.5 ml kg−1 to induce the acute injury 
model. Normal control rats received the same volume of olive oil. Eight rats in each group were 
randomly killed at 24 and 96 h after CCl4 administration and at the end of the study. The right 
lobes of the livers (0.5 g) were fixed in a 10% formaldehyde solution, embedded in paraffin and 
then processed for light microscopy. Another part of each liver was washed with saline, wiped 
dry, and then homogenized to 10% homogenate with cold saline for further biochemical 
measurement and metabolic profiling analysis.  
 
Twenty-four hour urine samples of each animal were collected from individually housed rats in 
metabolism cages at the initial day (I1), the 7th day (I7), and the 1st day (P1), the 4th day (P4), 
the 7th day (P7) and the 10th day (P10) post CCl4 administration (Table 1). At the end of the 
study, after the last time point (P10), urine samples were collected, all the rats were sacrificed 
and the serum and livers were collected for biochemical measurement. The urine samples were 
centrifuged at 10,000 rpm for 10 min to remove suspended debris and stored at −80°C. The 
animal experiment was carried out under the Guidelines for Animal Experiment of Shanghai 
University of Traditional Chinese Medicine (Shanghai, China), and the protocol was approved 
by the Animal Ethics Committee of the Shanghai University of Traditional Chinese Medicine. 
 
 
 
Table 1: Experimental design and sampling schedule  
Time (day) Abbreviations Experiment content Sampling 
1 I1 Initial time (pretreatment of DG) Urine 
7 I7 Initial time (pretreatment of DG) Urine 
14   CCl4 toxication    
15 P1 Post-toxication Urine, liver tissue, serum 
18 P4 Post-toxication Urine, liver tissue, serum 
21 P7 Post-toxication Urine 
24 P10 Endpoint Urine, liver tissue, serum 
 
 
Biochemistry and histopathology study  
Blood was collected at the 1st (P1), 4th (P4) day after CCl4 administration and at the end of the 
experiment (P10). Serum samples were then removed from the coagulated blood after 
centrifugation (10,000×g, 10 min, 4°C) and biochemical analysis was performed. Total 
cholesterol (TCHO) and serum enzymes, including aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT), were detected using an automatic biochemical analyzer (BST-370) to 
evaluate the severity of hepatic injury.  
 
Liver tissue was collected at the 1st (P1), 4th (P4) day after CCl4 administration and at the end of 
the experiment (P10). The liver malondiadehyde (MDA), superoxide dismutase (SOD) and 
glutathion peroxidase (GSH-px) content was detected with commercial Malondiadehyde Assay 
Kit, Superoxide Dismutase, and glutathion peroxidase Assay Kit (Jiancheng Bioengineer 
Institute, Nanjing, China), respectively. Briefly, liver tissues were homogenized with a T10 basic 
homogenizer (IKA, Staufen, Germany) for 30 s at 0°C before the procedures were conducted in 
strict accordance with instruction of the manufacturers. Values of MDA, SOD and GSH-px were 
obtained from the measurement and the standard curves.  
 
The same part of each liver sample was fixed in 10% (v/v) formalin for at least 12 h, and then 
processed into wax sections. Tissue sections were subsequently stained with haematoxylin and 
eosin (H–E), examined under a light microscope (OLYMPUS Co., Ltd, Japan) for the hepatic 
cell morphology evaluation, and captured by a digital camera.  
 
Data from the serum and tissue biochemistry determination were expressed as mean ± SD. 
Differences between the means of the treatment and control groups were analyzed using one-way 
analysis of variance (ANOVA). The critical P value was set at 0.05.  
 
Metabolic profiling of urine and hepatic tissue samples  
GC/MS-based metabolic profiling was performed on the urine samples following our established 
methods (Qiu et al. 2007). The urine samples were derivatized with ethylchloroformate (ECF). A 
600 μl of diluted urine sample (urine/water) 1:1, v/v) was added with 100 μl of L-2-
chlorophenylalanine (0.10 mg/ml, internal standard for batch quality control), 400 μl of 
anhydrous ethanol, 100 μl of pyridine and derivatized with 50 μl of ECF at room temperature, 
and then ultrasonicated at 100 kHz for 60 s. The derivatives were extracted with 300 μl of 
chloroform, and the pH was adjusted with 100 μl of NaOH (7 mol/l). The derivatization process 
was repeated by adding an additional 50 μl of ECF. The resulting mixtures were centrifuged at 
3000 rpm for 3 min. Then, the aqueous layer was removed and the chloroform layer containing 
derivatives was dehydrated with anhydrous sodium sulfate for subsequent GC/MS analysis. A 
1 μl aliquot of the derivatized extract was injected in splitless mode into an Agilent 6890N 
GC/5975B inert MSD (Agilent Technologies, Santa Clara, CA, USA). Separation was achieved 
on a DB-5MS capillary column.  
 
Each 100 mg liver tissue was extracted following the two-step extraction procedure described in 
our previous report (Pan et al. 2010). Briefly, for each 100-mg liver tissue sample, 500 μl of each 
of the two solvents (the mixture of chloroform, methanol and water (1:2:1, v/v/v) and methanol 
alone) were used as the two extraction solvents. After homogenization with the first solvent and 
centrifugation, a 150-μl aliquot of supernatant was transferred to a separate vial and the deposit 
was re-homogenized with the second solvent before a second centrifugation. Another 150-μl 
aliquot of supernatant was drawn out and mixed with the first 150-μl aliquot of supernatant. 
Then the 300 μl supernatant from the two extraction step was diluted with 300 μl of water. The 
600 μl solution was then derivatized with ECF using the aforementioned method.  
 
Either the injection temperature or the interface temperature was set to 260°C; and the ion source 
temperature was adjusted to 200°C. Initial GC oven temperature was 80°C; 2 min after injection, 
the GC oven temperature was raised to 140°C with 10°C min−1, to 240°C at a rate of 4°C min−1, 
to 280°C with 10°C min−1 again, and finally held at 280°C for 3 min. Helium was the carrier gas 
with a flow rate set at 1 ml min−1. The measurements were taken with electron impact ionization 
(70 eV) in the full scan mode (m/z 30–550).  
 
GC-MS Data Analysis  
The analysis of GC-MS data was performed with a minor modification to our established 
methods (Wang et al. 2009). Briefly, unprocessed GC/MS files were converted into NetCDF 
format via DataBridge (Perkin-Elmer Inc., U.S.A.) and directly processed by our custom scripts 
in MATLAB (The MathWorks, Inc., U.S.A.). This process performed data smoothing, filtering, 
de-noising, baseline correction, peak discrimination and alignment (for identification and 
extraction of the peaks of the chromatogram indicating the existence and intensities of potential 
metabolites), internal standard exclusion, and normalization to the total sum of the 
chromatogram (Bao et al. 2009; Wang et al. 2009; Pan et al. 2010). The resulting three-
dimensional (retention time, M/Z and Intensity of peaks) matrix was introduced into the SIMCA-
P 12.0 Software package (Umetrics, Umeå, Sweden) for multivariate statistical analysis. To 
ensure the consistency in spectral data transformation and avoid errors introduced to the data 
processing, we examined the peak areas with relatively high intensities and found no drastic 
fluctuations among those peaks. The data were mean-centered and then pareto-scaled. The mean-
centering procedure subtracts the mean of the data and results in a shift of the data towards the 
mean. The pareto-scaling technique gives the weight of each variable by the square root of its 
standard deviation, which amplifies the contribution of lower concentration metabolites but not 
to such an extent where noise produces a large contribution, this process enhances the 
identification of metabolites consistently present in the biological samples. The normalized data 
was analyzed by principal component analysis (PCA) to visualize general clustering, trends, or 
outliers among the observations. Then, partial least-squares-discriminant analysis (PLS-DA) was 
conducted to identify the metabolites differentially produced by CCl4 or DG. R2X and R2Y of 
the model represent the fraction of the variance, while Q2Y suggests the predictive accuracy of 
the model. The cumulative values of R2X, R2Y and Q2Y (range of 0 to 1) close to 1 indicate a 
satisfactory model. To avoid model over-fitting, the PLSDA model was carefully validated by an 
iterative 7-round cross-validation with 1/7 of the samples being excluded from the model in each 
round and random permutation tests (1,000 times).  
 
A VIP parameter (denoting the variable importance) of greater than 1, combined with a 
correlation coefficient pCorr (indicating the reliability of the loading and VIP value) of ±0.7 was 
adopted as the cutoff value for selecting the most important variables in terms of the PLSDA 
model, based on the integrated MS data (Wiklund et al. 2008). Differentially expressed variables 
were identified by chromatogram-MS data and labeled using thresholds of their fold change and 
P-values of their Kruskal–Wallis test. In addition to the nonparametric Kruskal–Wallis test, 
classical one-way analysis of variance (ANOVA) was also carried out to validate the statistical 
significance of these variables. The critical P value of Kruskal–Wallis and ANOVA was set at 
0.05 for this study. Compound identification of metabolites was performed by comparing the 
mass fragments of the significant variables with those present in commercially available mass 
spectral databases such as NIST, Wiley, NBS, and the library we established with a similarity 
threshed of 70%. Finally, about half of them were verified by reference compounds.  
 
RESULTS AND DISCUSSION 
Biochemistry and histopathology results  
As alanine aminotranferease (ALT) and aspartate aminotransferase (AST) are enzymes located 
in liver cells that are readily released into the general circulation when liver cells are injured, the 
two enzymes were measured to monitor the hepatocellular damage. At the 24th hour post CCl4 
administration, the activity of serum ALT and AST increased significantly, while the TCHO 
level decreased, as shown in Fig. 1. Pretreatment with DG significantly attenuated the alterations 
of several metabolite levels. At 96 h, the ALT, AST and TCHO activity of every animal in the 
study recovered to normal status. The value of MDA and SOD in liver changed significantly, and 
DG was able to attenuate the variation of MDA as well. The activity of GSH-px was altered by 
CCl4 and DG, but not significantly. At the end point of the study, hepatic MDA, SOD and GSH-
px levels returned to normal.  
 
The liver sections stained with H–E were examined for the histopathological assessment of CCl4 
induced liver injury and DG’s protection (Fig. 2). At the first day post injection of CCl4, 
significant damage to the hepatic histology structure, including cytoplasmic vacuolization, cell 
swelling, variations in cellular size and morphology and inflammatory cell infiltrations, was 
observed in most CCl4 challenged samples (Fig. 2b), compared with the normal liver 
morphologies in the NC group (Fig. 2a). Samples from the DG/CCl4 group illustrate reduced 
liver damage, e.g. intact liver structure and inconspicuous inflammatory cell infiltration (Fig. 2c). 
At 96 h post-dose of CCl4, all the damage was repaired and the histology showed no difference 
from the normal tissue (Fig. 2d, e). We ruled out the possible therapeutic effect due to the use of 
olive oil as a vehicle in our short-term (1–4 day) study, since the anti-inflammatory effects were 
generally observed in the subjects with relatively long-term (several weeks) dietary 
supplementation with olive oil (Beauchamp et al. 2005).  
 
Figure 1: Influence on plasma biochemical activities in rats at the 1,4,10 days after CCl4 injection (m ± s, n = 8). 
** P < 0.01, * P < 0.05 vs. NC ##  P < 0.01; #  P < 0.05 vs. CCl4  
 
 
Figure 2: Liver histology (*200) of chemical liver injury’s rats induced by CCl4. a NC group; (b) the 1st day post 
dose in CCl4 group; (c): the 1st day post dose in group; (d) the 4th day post dose in CCl4 group; (e) the 4th day post 
dose in DG/CCl4 group  
 
 
Metabolite Variation Induced by CCl4  
The PCA scores plot derived from the GC/MS data shows the clustering of NC and CCl4 groups 
on the first two principal components (PC1 and PC2), as depicted in Fig. 3a. The metabolomic 
result of this liver injury model displays stable cumulative modeled variation and good 
prediction capability with the first two components (Component Number = 3, R2Xcum = 0.626 
and Q2Ycum = 0.864). The 3-dimensional scores plot derived from the GC/MS data of the CCl4, 
DG/CCl4 and NC group is depicted in Fig. 3b (Component Number = 3, 
R2Xcum = 0.635,Q2Ycum = 0.408).  
 
 
 
Figure 3: Metabolic profiles depicted by 2D PCA scores plot of GC/MS spectral data from the urine of CCl4 and 
NC group (a: Component Number = 3, R2Xcum = 0.626 and Q2Ycum = 0.864), and 3D PCA scores plot of GC/MS 
spectral data from the urine of CCl4, DG/CCl4 and NC group (b: Component Number = 3, 
R2Xcum = 0.635,Q2Ycum = 0.408) 1 day post injection of CCl4  
 
 
The trajectories of PCA scores derived from the CCl4 (Component Number = 2, R2Xcum = 0. 
296,Q2Ycum = 0.170) and DG/CCl4 group (Component Number = 2, 
R2Xcum = 0.293,Q2Ycum = 0.109) were illustrated in Fig. 4. Transient shifts in the trajectory 
plot revealed the dynamic progress of the metabolic variation induced by CCl4 alone or in 
combination with DG treatment. In the CCl4 group, the metabolic profile on the first day post-
CCl4 injection (P1) was distinct from those of the other time-points. The trajectory demonstrates 
that the metabolic regulatory network underwent the most significant metabolic fluctuations on 
the first day of exposure to CCl4, and that the perturbed network underwent a recovery process 
during the following time points, returning to a stable profile close to the pre-dose state. This is 
consistent with the biochemical markers results. The time-dependent trajectory of metabolic 
alteration in the DG/CCl4 group appears similar to that in the CCl4 group. However, the 
metabolic perturbation in the DG/CCl4 group at the 1st and 4th day post-dose of CCl4 appeared 
less significant than those in the CCl4 group.  
 
 
Figure 4: PCA scores plots of GC/MS spectral data from model CCl4 group (a: Component Number = 2, 
R2Xcum = 0. 296,Q2Ycum = 0.170) and CCl4/DG group (C) visualized using a metabolic profiling approach, with 
the heatmap plot of differential expressed metabolites(b: Component Number = 2, 
R2Xcum = 0.293,Q2Ycum = 0.109) (filled square I1, open square I7, open diamond P1, filled triangle P4, filled 
diamond P7, open circle P10)  
 
 
We selected the different expressed metabolites in the rats of CCl4 group relative to NC group at 
the 1st day (P1) post CCl4 exposure, a key time point of liver injury study, and evaluated their 
variances at different time points of the DG/CCl4 group (Grizzi et al. 2003). Sixteen out of 21 
differentially expressed peaks, including amino acids such as alanine, glycine, proline, and 
glutamine, and organic acids such as citrate and hexanoate, were identified from spectral dataset, 
verified by reference standards (Fig. 4; Table 2). Univariate statistical methods, including one-
way ANOVA and the nonparametric Kruskal–Wallis test, were utilized to verify the significance 
of multivariate statistical method. The two heat-maps generated using differentially expressed 
metabolites in rats also indicate less significant fluctuation of metabolite levels (in fold change, 
relative to NC) in the DG/CCl4 group, suggesting that DG could attenuate the metabolic 
perturbation in the rats exposed to CCl4. These results support the clinical findings that DG has a 
protective effect on liver injuries. 
 
 
Table 2: List of identified differential metabolites in the urine samples of CCl4 and DG/CCl4 at 
1 day after CCl4 toxication, P values in CCl4 and DG/CCl4  
Metabolites RTa  VIPb  P c  
CCl4  DG/CCl4  
Hexanoated  6.06 1.45 0.0306 0.6770 
Phenylacetated  7.13 1.19 0.0003 0.0332 
Alanined  7.51 1.06 0.0359 0.1750 
Glycined  7.62 1.19 0.0049 0.0331 
Leucined  10.42 1.52 0.0049 0.0574 
Isoleucined  10.70 1.53 0.0427 0.3771 
Prolined  11.12 1.36 0.0206 0.1937 
Unknown 12.84 1.67 0.0382 0.3171 
Aspartated  14.03 1.29 0.0026 0.0526 
Glutamined  14.42 1.67 0.0004 0.0073 
3,4-dihydroxy-phenylacetated  14.87 1.09 0.0419 0.0203 
Citrated  15.05 1.21 0.0002 0.0031 
Unknown 15.28 1.33 0.0239 0.0552 
Unknown 16.01 1.07 0.0298 0.2346 
Unknown 17.42 1.02 0.0658 0.2600 
Phenylalanined  18.28 1.59 0.0273 0.2207 
4-hydroxy-phenylacetated  18.46 1.49 0.0467 0.0574 
Indol-3-acetated  21.28 1.19 0.0331 0.0426 
Tyramined  26.16 2.07 0.0002 0.0194 
4-ehtoxyphenyl-propenoated  29.55 1.69 0.0071 0.1296 
Unknown 33.46 1.81 0.0046 0.0172 
aRetention time of the metabolites in GC/MS  
bVariable importance in the projection (VIP) was obtained from PLS-DA  
c P values were calculated from Kruskal–Wallis test vs. NC group  
dMetabolites verified by reference compounds, others were directly obtained from library searching  
 
Significantly expressed metabolites in liver tissues were also analyzed by the Kruskal–Wallis test 
and classical one-way analysis of variance (ANOVA). P-values were set at 0.05. Figure 5 is the 
heat-map of the fold changes of differentially expressed metabolites in CCl4 and DG/CCl4 
groups, which consistently shows alleviative effect in DG/CCl4 group. Decreased levels of 
alanine, glycine, valine, leucine, arachidonate and eicosapentaenoate, increased levels of 
aspartate and oleate were observed in CCl4 group at the 1st (P1) and 4th day (P4). Except for 
arachidonate, the alteration of these metabolites was attenuated in DG/CCl4 group at the 4th day. 
There was no significant variation in the metabolites of liver tissues in the two groups at the last 
time point.  
 
 
Figure 5: Differential expressed metabolites in liver tissue the 1st and 4th day post intoxication  
Potential pathways associated with CCl4 and the DG treatment  
Our metabolic profiling strategy of urine and liver tissues is able to reveal the multi-pathway 
metabolic perturbation associated with CCl4 and the DG treatment, as summarized in Fig. 6. 
Since the liver is the hub of amino acids metabolism, any hepatic injury might induce amino 
acids metabolic disturbances. The metabolomic results showed that most of the amino acids that 
increased in urine and decreased in liver tissue, such as alanine, proline, glutamine, 
phenylalanine and isoleucine. Generally, the impact of acute liver injury on amino acids 
concentration results from three factors: protein synthesis and catabolism, BCAAs (branched 
chain amino acids) metabolism, and hepatic amino acid clearance. When damage occurs, 
catabolism promoting hormones, such as glucocorticoids and catecholamines, increase in 
secretion and decrease in deactivation, resulting in increased protein catabolism and therefore, 
increased levels of a number of amino acids in systemic circulation. Many amino acids are 
metabolized by liver enzymes and hence directly associated with the activity of hepatic enzymes. 
ALT and AST, two important enzymes in liver, were detected as well. Glutamine is an important 
amino acid for maintaining nitrogen balance (Brosnan 2003). A decrease in liver and an increase 
in urinary excretion of glutamine may be associated with an outflow of AST from hepatocellular 
mitochondrion and an indication of impaired hepatic regulating function. Branched chain amino 
acids (BCAAs), such as valine, isoleucine and leucine, are essential amino acids typically 
involved in stress, energy and muscle metabolism (Choudry et al. 2006). In our study, an 
increased level of isoleucine and leucine in urine, while decreased levels of hepatic valine, 
leucine and isoleucine were observed in CCl4 group at the 1st and 4th day post CCl4 injection 
(P1, P4). When protein catabolism is being observed, as in some cases of severe toxicity, the 
BCAAs are used in muscle to create alanine, which is then shuttled to the liver (Holecek et al. 
1996). Normally blood alanine is transported to liver via glucose-alanine cycle to generate 
pyruvate which becomes a source of carbon atoms for gluconeogenesis. Alanine was found 
largely excreted in urine and decreased in liver tissue, suggesting an impaired glucose-alanine 
cycle due to the CCl4 exposure. DG attenuated the altered levels of alanine and BCAAs but 
didn’t affect citrate level, suggesting that DG’s interaction is involved in the glucose-alanine 
cycle and its closely associated amino acids metabolism. It was not able to ameliorate the citrate 
expression level as part of the impaired TCA cycle, whose metabolic enzymes located in 
mitochondria (Fig. 6).  
 
Aspartic acid is vitally important to the metabolism and construction of many amino acids and 
intermediates in the tricarboxylic acid (TCA) cycle. It has also shown a protective action on the 
liver by its capacity to reestablish the cellular deficit of pyridine nucleotides and thus improve 
the synthesis of nucleic acids, glycoprotein and glycolipids and/or by its participation in various 
metabolic pathways (Fodor et al. 1976). In this study, aspartate remained a significant higher 
concentration in the liver at the 1st and 4th day post CCl4 injection, while its decrease in urine 
excretion could be resisted by either recovery time or DG treatment.  
 
Urinary and hepatic glycine levels significantly decreased after CCl4 exposure. The large 
amounts of oxygen free radicals generated from CCl4 dose altered hepatic levels of MDA, SOD 
and GSH-px. As a result, the anti-oxidants involving reduced glutathione hormone (GSH) were 
presumably over-consumed. As glutathione is synthesized from the amino acids L-cysteine, L-
glutamate and glycine, it is understandable that glycine was found significantly depleted soon 
after CCl4 exposure. However, we were surprised to detect a drastically increased level of 
glycine in urine (Fig. 4a) while decreased in the liver (Fig. 5, P4) 4 days after toxication. Recent 
research has indicated that glycine significantly decreases liver injury via a direct effect on 
hepatocytes (Froh et al. 2008). As the decreased hepatic glycine level was normalized by DG at 
both the 1st and 4th day after injury, we presumed that the elevation of glycine in the urine may 
be beneficial to the recovery of hepatic cells. The urinary glycine level also displayed a rebound 
in DG/CCl4 group at P4.  
 
 
 
Figure 6: Potential metabolic mechanisms of CCl4 induced toxicity and the protection of Diammonium 
glycyrrhizinate. All the colored character styles were connected with CCl4 induced toxicity. Green: DG effective 
metabolites; Red: DG ineffective metabolites; Orange: biochemical indices  
 
 
Furthermore, several compounds containing benzene ring, such as phenylacetate, phenylalanine, 
4-hydroxy-phenylacetate, indol-3-acetate, tyramine, 3, 4-dihydroxy-phenylacetate and 4-
ethoxyphenyl-propenoate were discovered significantly altered in the urine of CCl4 treated rats, 
as compared to the normal group. These metabolites are mainly produced from aromatic 
compounds, especially aromatic amino acids. Indol-3-acetate, namely indoleacetic acid (IAA) is 
produced in tryptophan metabolism often with involvement of bacteria in the mammalian gut 
(Maillet et al. 2009). It is believed to be a product of the decarboxylation of tryptamine or the 
oxidative deamination of tryptophan. Tyramine is formed by decarboxylation of tyrosine in 
tissues as well as in the gut (Asatoor 1968). Phenylacetate can be produced by the transamination 
and then decarboxylation of excess phenylalanine, an important precursor of tyrosine, which 
decreased in liver and increased in urine at the 1st day post dose. 4-hydroxy-phenylacetate is an 
oxidative deaminated metabolite of tyramine and also a metabolite of tyrosine from enteric 
bacteria (Rechner et al. 2004, Nowak and Libudzisz 2006). Another phenolic acid, 3, 4-
dihydroxy-phenylacetate, commonly called DOPAC, is the product of oxidation of the aldehyde 
produced by deamination metabolite from dopamine, one of the catecholamines derived from 
tyrosine (Goldstein et al. 2003). DOPAC is also one of the major phenolic acids formed during 
gut microbial fermentation of diets. The variation of these metabolites may reflect either an 
alteration in a disturbed symbiotic gut microbiota and/or the catecholamine metabolic pathway. 
Furthermore, the aromatic metabolites still fluctuated at the P4 and P7, and finally returned to the 
normal level, suggesting that the impact of CCl4 on the metabolism of aromatic compounds 
lasted longer than its impact on other metabolic pathways. The normalized expression level of 
these metabolites in the DG/CCl4 group suggests a protective effect of DG on gut microbiota 
and/or catecholamine pathways.  
 
It has been reported that CCl4 derived free radicals may attack polyunsaturated fatty acids 
(PUFA) in cell membranes, forming fatty acid free radicals, which initiate an autocatalytic lipid 
peroxidation process and generate more lipid hydroperoxides and reactive hydroxyalkenals 
during membrane disruption (Vulimiri et al. 2010; Catala 2009). The toxin, CCl4, can also 
promote the production of fatty acids and triglyceride inside the liver, accelerate the lipid 
esterification and cholesterols synthesis, and thus, lower the content of partially unsaturated fatty 
acids (Boll et al. 2001). In our results, octadecanoate, arachidonate and eicosapentaenoate 
decreased in tissue samples at the 1st or 4th day. We found that the hepatic content of oleate 
increased at both the 1st and 4th day. DG significantly inhibited the alteration of these fatty acids 
except arachidonate, suggesting that the anti-inflammatory effect of DG is not directly associated 
with arachidonate metabolism.  
 
CONCLUDING REMARKS 
Our metabolic profiling has revealed the CCl4 induced alterations in amino acid, TCA, lipid and 
gut microbiota metabolism. Most of these metabolic alterations could be attenuated by 
Diammonium glycyrrhizinate. This global metabolomic approach also revealed that the 
experimental rats required a prolonged recovery in metabolic profile, although the histological 
results and biochemical markers indicated a rapid recuperation from CCl4 induced liver injury. 
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ABBREVIATIONS 
DG   Diammonium glycyrrhizinate 
NC   Normal control 
TCHO  Total cholesterol 
AST   Aspartate aminotransferase 
ALT   Alanine aminotransferase 
MDA   Malondiadehyde 
SOD   Superoxide dismutase 
GSH-px  Glutathion peroxidase 
ECF   Ethylchloroformate 
PCA   Principal component analysis 
PLS-DA  Partial least squares discriminant analysis 
PC   Principal component 
GSH   Reduced glutathione 
GSSG   Oxidized glutathione 
DOPAC  3,4-Dihydroxy-phenylacetate 
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